As the legal world turns its gaze towards the ongoing litigation between REGENXBIO Inc. and Sarepta Therapeutics, the latest developments come in the form of a scheduling order issued by the courts. This order comes after a claim, filed in Delaware in June 2023, by both REGENXBIO Inc. and the Trustees of the University of Pennsylvania against Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC, and Catalent, Inc.
The plaintiffs in this case allege that Sarepta’s gene therapy product, ELEVIDYS (delandistrogene moxeparvovec-rokl), infringes on U.S. Patent No. 11,680,274. This has garnered much attention within the wider legal and scientific industries, marking yet another milestone in the complex field of gene therapy litigation.
The current scheduling order potentially sets the pace and timeline for future developments in this case. Specific details relating to this order, however, have not been disclosed publicly at the time of writing. This makes predicting specific next steps in the litigation a challenging task for legal observers and participants alike.
As the case unfolds, many will be watching closely to see how it could potentially impact not only REGENXBIO and Sarepta, but also the broader gene therapy and biotechnology sectors. With the increasing amount of patent disputes in these rapidly evolving fields, the outcome could set a crucial precedent for future cases.
For continued coverage of this development, you can check out the report on JD Supra. Their in-depth reports offer a comprehensive understanding of the intricate legal cases shaping the future of biotechnology.